This study assessed the possible roles of metabolic/obesity phenotypes and vitamin D status (as documented in the UK Biobank prospective cohort survey) in increasing COVID-19 severity in a group with a mean age of 67.7 years...
In this prospective study, the self-reported use of vitamin D supplements was associated with a lower risk of COVID-19 infection, independent of lifestyle, socio-economic status, prevalent chronic diseases and circulating...
In this study involving 118 patients at the San Paolo Hospital in Miliam Italy, a significant proportion of COVID-19 patients had vitamin D deficiency and patients requiring...
25-OH-vitamin D 25(OH)D deficiency (less than 50 nmol/L) was associated with both a more severe systemic inflammatory response and respiratory failure in a group of hospitalized, older (mean age, 69.4 years) COVID-19 positive patients in Italy.
This observational study suggests that a high proportion (70.3%) of patients hospitalized with COVID-19 had vitamin-D deficiency that the general UK population, however, there were no measurable differences in overall clinical outcomes between...
Results from this retrospective analysis demonstrate that two consecutive doses of 200,000 IU cholecalciferol (total of 400,000 IU) can significantly improve the outcome in patients affected by COVID-19 that are also burdened with three or more...
Among patients admitted with laboratory-confirmed COVID-19, low serum vitamin D [25(OH)D] levels were associated with greater in-hospital mortality and need for invasive mechanical ventilation...
This study of 204 patients, suggests that adequate (25(OH)D of >50 nmol/L) levels of vitamin D may play a role in inflammation and reduce the severity of COVID-19.
After adjusting for demographic variables and comorbidities, this retrospective analysis of COVID-positive patients in New York City, shows a significant association between low 25(OH)D levels and an increased likelihood of need for oxygen support.
In this observational study, treatment with cholecalciferol booster therapy, regardless of baseline serum 25(OH)D levels, appears to be associated with a reduced risk of mortality in acute in-patients admitted with COVID-19.
